Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: The 6.6 magnitude quake hit early on Tuesday, damaging buildings, toppling power lines and triggering landslides in the central area of the Philippines’ southern island. A seven-year-old child and his 44-year old father were among those who were killed in the North Cotabato province after they were struck by a boulder, disaster officials said. Authorities said the death toll could rise further because many injured were not immediately brought to hospitals. “It was depressing to see the damage left by the earthquake,” Abril Espadera, a disaster official in North Cotabato, told Reuters, as he recalled seeing collapsed homes and demolished buildings in the province, including schools. Smaller tremors rattled nervous residents throughout the day and those who were afraid to return to their homes set up tents to shelter near school yards, Espadera said. In Magsaysay town in Davao del Sur province, rescuers were trying to recover three bodies after landslides in two separate towns swallowed parts of agricultural areas, police said. The quake, whose magnitude was initially put at 6.7 by the European-Mediterranean Seismological Centre, was the second powerful quake to strike Mindanao in two weeks. Authorities had flagged the risk of landslides after the 6.3 quake on Oct. 16 in central Mindanao that killed seven and injured more than 200. Earthquakes are common in the Philippines, which is on the geologically active Pacific Ring of Fire. Power cables swayed in Davao city, the home town of President Rodrigo Duterte, where people rushed to open spaces, and some fainted out of fear. The quake also triggered power cuts in nearby General Santos city, media said. Some schools in the area have suspended classes. Duterte’s office has called for calm as it mobilized all government agencies to undertake damage assessment and to coordinate rescue and relief operations.
[EX A]: Death toll in southern Philippines earthquake rises to seven.

[EX Q]: "With abortion now a key issue in the debate over health care reform, abortion rights supporters are highlighting President Barack Obama's promise about the issue during the presidential campaign. In an alert to members on Nov. 9, 2009, Planned Parenthood Action Fund said, ""President Obama campaigned on a promise to put reproductive health care at the center of his reform plan."" We'll address that claim here. We'll also be adding it to our Obameter database of campaign promises. The group's claim is virtually identical to one made in September by House Republican Leader John Boehner, R-Ohio, who said in a statement that, ""during his quest for the presidency, now-President Obama declared that everyone deserves access to reproductive health care that includes abortion, and vowed that this 'right' would be at the heart of his health care reform plan if elected president."" We researched Boehner's claim and concluded he was right about Obama's promise. To explore Obama's promise on abortion coverage in his health care plan, you need to go back to a July 17, 2007, speech he gave to the Planned Parenthood Action Fund. In that speech, he discussed his commitment to how ""reproductive care"" -- a term a campaign aide said included abortion coverage -- would fit into his health care reform plan. Obama said, ""In my mind, reproductive care is essential care. It is basic care, so it is at the center and at the heart of the plan that I propose. Essentially what we're doing is, we’re going to set up a public plan that all persons and all women can access if they don’t have health insurance. It will be a plan that will provide all essential services, including reproductive services, as well as mental health services and disease management services, because part of our interest is to make sure that we’re putting more money into preventive care."" The words Obama used in that speech mirror those in the Planned Parenthood Action Fund's recent alert even more closely than they did Boehner's formulation. So it's certainly correct, as the group says, that Obama ""campaigned on a promise to put reproductive health care at the center of his reform plan."" It's worth nothing that since he spoke to that group -- an important constituency for someone seeking the Democratic nomination -- he has chosen his words carefully. Of all the words Obama has spoken and written about health care reform since 2007 -- a voluminous amount, to be sure -- the terms ""abortion"" and ""reproductive health"" haven't popped up very often. Indeed, on several of the rare occasions in which Obama or his staff have broached the subject, it's been to assure Americans that his health care proposal would not promote abortions. For instance, in his prime-time address to Congress on Sept. 9, 2009, Obama's only mention of abortion -- which came immediately after he was interrupted by the heckling Rep. Joe Wilson, R-S.C. -- was that ""one more misunderstanding I want to clear up: Under our plan, no federal dollars will be used to fund abortions, and federal conscience laws will remain in place."" That's a reflection of the sensitivity surrounding the issue. Obama's promise to the abortion rights group during the primary campaign could now be a liability before a broader audience that includes many people opposed to abortion rights. Still, Planned Parenthood is correct that Obama campaigned on a promise that he would put reproductive health care at the center of his reform plan."" After all, he was speaking to . . . Planned Parenthood. So we find the group's claim to be ."
[EX A]: President Obama campaigned on a promise to put reproductive health care at the center of his reform plan.

[EX Q]: Although Pfizer continues to test the drug, called dacomitinib, in another Phase III study, hopes for its success have now largely faded, according to ISI Group analyst Mark Schoenebaum. “We believe consensus expectations (for the drug) will be close to zero given today’s readout” of unsuccessful trial results, Schoenebaum said in a research note. In one of the failed trials, called ARCHER 1009, patients given Pfizer’s once-daily pill did not show improved survival without the cancer worsening, compared with Roche Holding AG’s widely used Tarceva (erlotinib). Tarceva is the current standard of care in patients with mutated forms of a protein called Epidermal Growth Factor Receptor (EGFR). The protein plays a role in normal regulation of cell growth, but when mutated is believed to cause cells to proliferate and thereby help spur various types of cancer. Dacomitinib is designed to block several types of Epidermal Growth Factor receptors, while Tarceva and similar treatments for lung cancer target only one type of receptor. Cowen and Co had forecast annual sales of $500 million by 2020 for dacomitinib, if it were approved for lung cancer. That would make it a moderate-sized product for Pfizer, the largest U.S. drugmaker, which has annual revenue of $50 billion. Schoenebaum said there has been little investor interest in the drug and that Wall Street had expected it to generate annual sales of only $300 million by 2018. The second failed trial, named BR.26, involved patients that previously had failed to benefit from chemotherapy as well as from treatment with an EGFR inhibitor. Overall survival of patients taking the Pfizer drug was not prolonged in the study, compared with patients given a placebo. Pfizer said adverse events seen with dacomitinib were consistent with those seen in smaller earlier studies. In the meantime, Pfizer said dacomitinib is also being tested in a third late-stage trial, called ARCHER 1050, among patients with advanced non-small cell lung cancer who have not received prior treatment. The study will compare dacomitinib with Iressa (gefitinib), an EGFR inhibitor sold by AstraZeneca Plc. Results from that study are expected in 2015. Pfizer shares were little changed in morning trading on the New York Stock Exchange.
[EX A]:
Pfizer lung cancer drug fails in two large studies.